JP2017155056A5 - - Google Patents

Download PDF

Info

Publication number
JP2017155056A5
JP2017155056A5 JP2017111625A JP2017111625A JP2017155056A5 JP 2017155056 A5 JP2017155056 A5 JP 2017155056A5 JP 2017111625 A JP2017111625 A JP 2017111625A JP 2017111625 A JP2017111625 A JP 2017111625A JP 2017155056 A5 JP2017155056 A5 JP 2017155056A5
Authority
JP
Japan
Prior art keywords
moiety
compstatin analog
peg
formula
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017111625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017155056A (ja
JP6653294B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017155056A publication Critical patent/JP2017155056A/ja
Priority to JP2019129901A priority Critical patent/JP6905554B2/ja
Publication of JP2017155056A5 publication Critical patent/JP2017155056A5/ja
Application granted granted Critical
Publication of JP6653294B2 publication Critical patent/JP6653294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017111625A 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 Active JP6653294B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019129901A JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161484836P 2011-05-11 2011-05-11
US61/484,836 2011-05-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014510520A Division JP6522337B2 (ja) 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019129901A Division JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Publications (3)

Publication Number Publication Date
JP2017155056A JP2017155056A (ja) 2017-09-07
JP2017155056A5 true JP2017155056A5 (enExample) 2019-09-05
JP6653294B2 JP6653294B2 (ja) 2020-02-26

Family

ID=47139714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014510520A Active JP6522337B2 (ja) 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2017111625A Active JP6653294B2 (ja) 2011-05-11 2017-06-06 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
JP2019129901A Active JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014510520A Active JP6522337B2 (ja) 2011-05-11 2012-05-11 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019129901A Active JP6905554B2 (ja) 2011-05-11 2019-07-12 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用

Country Status (13)

Country Link
US (5) US10125171B2 (enExample)
EP (2) EP2707384B1 (enExample)
JP (3) JP6522337B2 (enExample)
CN (2) CN107050422B (enExample)
AU (3) AU2012253294B2 (enExample)
BR (1) BR112013028816B1 (enExample)
CA (1) CA2835627C (enExample)
DK (1) DK2707384T3 (enExample)
ES (1) ES2915265T3 (enExample)
IL (3) IL265344B2 (enExample)
MX (2) MX385001B (enExample)
RU (1) RU2653439C9 (enExample)
WO (1) WO2012155107A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2461241A1 (en) 2010-12-03 2012-06-06 Research In Motion Limited Soft key with main function and logically related sub-functions for touch screen device
CA2835627C (en) 2011-05-11 2023-01-10 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
EP3929206A1 (en) * 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2016138520A1 (en) * 2015-02-27 2016-09-01 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CA3287719A1 (en) * 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
CN105777893B (zh) * 2016-03-24 2019-10-25 杭州亚慧生物科技有限公司 一种高强度血清白蛋白骨修复材料及其制备方法
EP3526328A4 (en) * 2016-10-17 2020-05-27 Apellis Pharmaceuticals, Inc. COMBINATION THERAPY FOR C3 INHIBITION
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA
CN107722262B (zh) * 2017-09-18 2020-11-24 华南理工大学 一种聚碳二亚胺类聚合物及其制备方法与应用
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
WO2019195712A2 (en) 2018-04-06 2019-10-10 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
BR112021011727A2 (pt) 2018-12-17 2021-08-31 Achillion Pharmaceuticals, Inc Dosagem direcionada para o tratamento de distúrbios mediados do complemento
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CN110624274B (zh) * 2019-08-27 2021-04-13 苏州赛分科技有限公司 分离介质及其制备方法和应用
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
AU2022383173A1 (en) * 2021-11-03 2024-05-23 Apellis Pharmaceuticals, Inc. Complement inhibitor dosing regimens
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
WO2026083442A1 (en) 2024-10-15 2026-04-23 Mylan Laboratories Limited Process for the preparation of pegcetacoplan and its purification using chromatography

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
KR20010006280A (ko) 1997-04-11 2001-01-26 어드밴스드 메디슨 인코포레이티드 다수개의 활성 잔기를 제공하는 분자
WO1998047002A2 (en) 1997-04-11 1998-10-22 Advanced Medicine, Inc. Polyvalent presenter combinatorial libraries and their uses
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
DK1549333T3 (da) 2002-09-20 2012-01-16 Univ Pennsylvania Compstatinanaloge med forbedret aktivitet
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2625206C (en) 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US20070134244A1 (en) 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
PT2500030E (pt) * 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
CN106188239B (zh) 2005-11-28 2020-01-07 宾夕法尼亚州大学理事会 有效的坎普他汀类似物
CL2007003044A1 (es) 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
CN101795695B (zh) 2007-07-19 2016-01-06 阿列克斯塞尔公司 作为抗癌剂的自组装的两亲性聚合物
US20110092446A1 (en) 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009046198A2 (en) 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CN102458438A (zh) * 2009-05-01 2012-05-16 宾夕法尼亚州大学理事会 具有肽骨架和c-末端修饰的经修饰补体抑素
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US8625635B2 (en) 2010-04-26 2014-01-07 Cleversafe, Inc. Dispersed storage network frame protocol header
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
CA2835627C (en) 2011-05-11 2023-01-10 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
EP3929206A1 (en) 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JP6159886B2 (ja) 2013-07-16 2017-07-05 北京机械▲設▼▲備▼研究所 高層及び超高層ビルの消火活動に適用する消防車
US9806963B2 (en) 2013-10-18 2017-10-31 Cellco Partnership Feature activation on device
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法

Similar Documents

Publication Publication Date Title
ES2397852T3 (es) Antagonistas y conjugados de péptidos CGRP
JP6525471B2 (ja) ヘプシジン類似体及びその使用
JP2022514618A5 (enExample)
JP2019206547A5 (enExample)
ES2703110T3 (es) Composiciones y métodos de uso de péptidos de neogénesis insular y análogos de los mismos
JP2011511778A5 (enExample)
JP2014514364A5 (enExample)
JP2017523959A (ja) ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用
RU2010103995A (ru) Бифункциональные слитые белки альфа-меланоцитостимулирующего гормона (альф-msh) и атриального натрийуретического белка (anp) и их применение при гипертонии и остром повреждении почек
AR106920A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
EP3749345A1 (en) Conjugated hepcidin mimetics
ES2692722T3 (es) Composición de recubrimiento de microagujas y dispositivo de microagujas
TW201028162A (en) Amide based glucagon superfamily peptide prodrugs
JP2009532384A5 (enExample)
AR105817A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
EP2648758A1 (en) Bio-functionalized stimulus-responsive dissolvable peg-hydrogels
US11884747B2 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
JP2011511753A5 (enExample)
JP2019501867A5 (enExample)
TW201209062A (en) Amide based glucagon superfamily peptide prodrugs
RU2014117678A (ru) Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
JP2013543497A5 (enExample)
JP2015532283A5 (enExample)
RU2018116446A (ru) Схемы введения
RU2013146690A (ru) Циклические пептиды с антинеопластической и антиангионенной активностью